GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

As well as new Joy-Cons (which appear to also function as a mouse, thanks to optical sensors), the Switch 2’s new design has another quality-of ... C (especially the high-end Thunderbolt ...

There are reportedly still ongoing conversations between the New York Mets and Pete Alonso, although the team is hoping for a relatively quick solution. Joel Sherman and Jon Heyman of the New York ...

Instead, Walmart gave its logo a makeover fit for modern times ... “The awareness of the brand is so high that to completely change it would invite even more ire,” says Bruno Benedini ...

YOUNGSTOWN, Ohio – Flying High Inc. on Thursday unveiled a new logo that celebrates 30 years of service to the community and embodies the strength, resilience and hope that are central to its mission.

Geospatial AI chief executive officer Mohammad Fadhli Jamaluddin said that Uzma SAT-1, now in low Earth orbit at approximately 500 kilometres altitude, is capable of producing high-resolution ...

Walmart announced on Monday that it had unveiled a new logo, part of "a comprehensive brand refresh." The U.S.-based retailer boasted in a news release that the new look — its first change ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report ... The company has a one-year high of p1,823.50 and a one-year ...

Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from ...

GSK has a twelve month low of $31.72 and a twelve month high of $45.92. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The firm also recently ...

GSK has announced a definitive agreement to acquire IDRx, a US-based biotechnology company specialising in treatments for gastrointestinal cancers, for up to $1.15bn in cash, marking the first ...